Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACSTNASDAQ:ATOSNASDAQ:CLSNOTCMKTS:CPMDNASDAQ:CYCC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACSTAcasti Pharma$3.13+6.8%$3.33$1.72▼$3.84$29.42M1.4925,679 shs1,835 shsATOSAtossa Therapeutics$1.54+1.3%$1.43$0.59▼$2.31$192.96M1.21.39 million shs455,141 shsCLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsCPMDCannaPharmaRX$0.01$0.01$0.00▼$0.03$6.61M2.12659,914 shsN/ACYCCCyclacel Pharmaceuticals$1.52-5.0%$2.31$1.41▼$13.20$2.01M0.54175,798 shs118,431 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACSTAcasti Pharma-0.39%-4.30%-13.87%+14.84%+8.37%ATOSAtossa Therapeutics+1.33%+7.04%-15.56%+85.37%+151.45%CLSNImunon0.00%0.00%0.00%0.00%0.00%CPMDCannaPharmaRX0.00%0.00%-39.39%+614.29%0.00%CYCCCyclacel Pharmaceuticals-29.82%-13.51%-17.95%-24.53%-82.25%How a $0.25 cent option contract makes my top traders feel (Ad)If you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…Click now to see for yourself what $0.25 Cent Trades is all aboutMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACSTAcasti Pharma2.2919 of 5 stars3.53.00.00.01.70.81.3ATOSAtossa Therapeutics1.0928 of 5 stars3.51.00.00.01.71.70.0CLSNImunonN/AN/AN/AN/AN/AN/AN/AN/ACPMDCannaPharmaRXN/AN/AN/AN/AN/AN/AN/AN/ACYCCCyclacel Pharmaceuticals1.295 of 5 stars3.33.00.00.01.50.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACSTAcasti Pharma3.00Buy$6.0091.69% UpsideATOSAtossa Therapeutics3.00Buy$4.50192.21% UpsideCLSNImunonN/AN/AN/AN/ACPMDCannaPharmaRXN/AN/AN/AN/ACYCCCyclacel Pharmaceuticals2.50Moderate Buy$21.001,281.58% UpsideCurrent Analyst RatingsLatest CLSN, ATOS, CPMD, ACST, and CYCC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.004/2/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.002/12/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$4.002/7/2024ACSTAcasti PharmaCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACSTAcasti PharmaN/AN/AN/AN/A$9.14 per shareN/AATOSAtossa TherapeuticsN/AN/AN/AN/A$0.73 per shareN/ACLSNImunon$500K0.00N/AN/A$9.66 per share0.00CPMDCannaPharmaRXN/AN/AN/AN/A($0.07) per shareN/ACYCCCyclacel Pharmaceuticals$420K4.78N/AN/A$0.57 per share2.67Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACSTAcasti Pharma-$42.43M-$5.08N/AN/AN/AN/A-13.18%-11.32%6/28/2024 (Estimated)ATOSAtossa Therapeutics-$30.09M-$0.24N/AN/AN/AN/A-31.01%-29.77%5/20/2024 (Estimated)CLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/ACPMDCannaPharmaRX-$8.53M-$0.03N/A∞N/AN/AN/A-141.66%N/ACYCCCyclacel Pharmaceuticals-$22.56M-$27.22N/AN/AN/AN/A-448.19%-151.29%5/9/2024 (Estimated)Latest CLSN, ATOS, CPMD, ACST, and CYCC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023ATOSAtossa TherapeuticsN/A-$0.06-$0.06-$0.06N/AN/A3/19/2024Q4 2023CYCCCyclacel Pharmaceuticals-$6.35-$6.23+$0.12-$6.23N/A$0.03 million2/12/202412/31/2023ACSTAcasti Pharma-$0.23-$0.21+$0.02-$0.21N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACSTAcasti PharmaN/AN/AN/AN/AN/AATOSAtossa TherapeuticsN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/ACPMDCannaPharmaRXN/AN/AN/AN/AN/ACYCCCyclacel PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACSTAcasti PharmaN/A15.1915.19ATOSAtossa TherapeuticsN/A17.6117.61CLSNImunon0.136.526.52CPMDCannaPharmaRXN/AN/AN/ACYCCCyclacel PharmaceuticalsN/A0.910.91OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACSTAcasti Pharma6.08%ATOSAtossa Therapeutics12.74%CLSNImunon12.97%CPMDCannaPharmaRXN/ACYCCCyclacel Pharmaceuticals23.58%Insider OwnershipCompanyInsider OwnershipACSTAcasti Pharma13.51%ATOSAtossa Therapeutics7.80%CLSNImunon4.66%CPMDCannaPharmaRX1.27%CYCCCyclacel Pharmaceuticals8.47%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACSTAcasti Pharma329.40 million8.13 millionNot OptionableATOSAtossa Therapeutics12125.30 million115.53 millionOptionableCLSNImunon277.10 million6.77 millionOptionableCPMDCannaPharmaRX6660.63 million652.24 millionNot OptionableCYCCCyclacel Pharmaceuticals2,0181.32 million1.21 millionOptionableCLSN, ATOS, CPMD, ACST, and CYCC HeadlinesSourceHeadlineCyclacel Pharmaceuticals Shares Hit All-Time Low on Planned Equity Salemarketwatch.com - April 26 at 7:08 AMCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Is Expected To Breakeven In The Near Futurefinance.yahoo.com - April 25 at 9:41 AMCyclacel Pharmaceuticals (NASDAQ:CYCC) Receives New Coverage from Analysts at StockNews.comamericanbankingnews.com - April 24 at 2:38 AMAnalyzing Lexicon Pharmaceuticals (NASDAQ:LXRX) & Cyclacel Pharmaceuticals (NASDAQ:CYCC)americanbankingnews.com - April 20 at 2:00 AMCyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.comamericanbankingnews.com - April 16 at 2:28 AMCyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancerglobenewswire.com - April 1 at 9:15 AMCyclacel Pharmaceuticals Incmoney.usnews.com - March 27 at 4:39 AMCyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 21 at 3:27 AMCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 20 at 12:21 PMCYCC Stock Earnings: Cyclacel Pharmaceuticals Misses EPS for Q4 2023msn.com - March 19 at 9:26 PMCyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateglobenewswire.com - March 19 at 4:05 PMCyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - March 13 at 4:05 PMCyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024globenewswire.com - March 7 at 9:15 AMCyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Creditglobenewswire.com - March 6 at 9:15 AMCyclacel Pharmaceuticals, Inc. (CYCCP)finance.yahoo.com - February 22 at 2:10 PMCyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conferenceglobenewswire.com - February 20 at 9:15 AMCyclacel Pharmaceuticals Inc. (UXI.SG)finance.yahoo.com - February 15 at 7:46 AMCyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirementfinance.yahoo.com - January 8 at 10:11 AMRecent Insider Activity Suggests Potential Gains for Cyclacel Pharmaceuticals Inc (CYCC)knoxdaily.com - January 1 at 2:59 PMWhy Cyclacel Pharmaceuticals (CYCC) Shares Are Getting Obliteratedmsn.com - December 22 at 12:40 PMCyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - December 22 at 12:40 PMCYCC Stock Earnings: Cyclacel Pharmaceuticals Misses EPS for Q3 2023investorplace.com - December 20 at 11:12 AMCYCC Stock Earnings: Cyclacel Pharmaceuticals Beats EPS for Q2 2023investorplace.com - December 20 at 11:12 AMCYCC Stock Earnings: Cyclacel Pharmaceuticals Beats EPS for Q1 2023investorplace.com - December 20 at 11:12 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAcasti PharmaNASDAQ:ACSTAcasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.Atossa TherapeuticsNASDAQ:ATOSAtossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.ImunonNASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.CannaPharmaRXOTCMKTS:CPMDCannaPharmaRX, Inc. operates in the cannabis industry in Canada. It evaluates, negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.Cyclacel PharmaceuticalsNASDAQ:CYCCCyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.